论文部分内容阅读
本实验对40例空腹血糖(FPG)≥15.0mmol/L,随机血糖≥17.4mmol/L的2型糖尿病患者进行诺和锐强化治疗,结果表明诺和锐强化治疗降低空腹血糖和餐后血糖效果更好。
In this study, 40 patients with type 2 diabetes with fasting blood glucose (FPG) ≥15.0mmol / L and random blood glucose≥17.4mmol / L were treated with Novo-sharp treatment. The results showed that Novo-intensive therapy reduced fasting blood glucose and postprandial blood glucose better.